DELIVERING

INNOVATION +

IMPROVING LIVES

HALF-YEAR RESULTS 2022

JULY 28, 2022

Safe harbour

This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management.

The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its plans will be achieved. Actual results may differ materially from those set forth in this presentation due to the risks and uncertainties inherent in Cosmo's ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialization of its product candidates and reduce costs (including staff costs). Any statements regarding the development of the

market for drugs to treat IBD diseases, Cosmo's anticipated

future revenues, capital expenditures, financial resources and other similar statements, may be "forward-looking" and as such involve risks and uncertainties and risks related to the collaboration between Cosmo and its current or future partner and/or any business activities that are integrated into

Cosmo's business and risks following any potential for delays in the development programs for its products. No assurance can be given that the results anticipated in such forward-looking statements will occur. Actual events or

results may differ materially from Cosmo's expectations due to factors which include, but are not limited to, a lack of information regarding any future partners or acquisitions, increased competition, Cosmo's ability to finance expansion plans, the results of Cosmo's research and development activities, the success of Cosmo's products and

partnerships, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Cosmo assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Cosmo undertakes no obligation to revise or update this presentation.

Cosmo Pharmaceuticals | Half Year Results 2022

2

01 Introduction

Alessandro Della Chà - CEO

02 H1 2022 Key Events & Products Update Alessandro Della Chà - CEO

03 2022 Financial Review Niall Donnelly - CFO

04 2022 Key Priorities & Guidance Alessandro Della Chà - CEO

Cosmo Pharmaceuticals | Half Year Results 2022

3

INTRODUCTION

ALESSANDRO DELLA CHÀ CEO

Cosmo Pharmaceuticals | Half Year Results 2022

4

Who we are

Cosmo is a pharmaceutical company which develops and manufactures innovative products in the fields of:

Gastroenterology

HealthTech

Dermatology

Gastrointestinal (GI) diseases

Artificial Intelligence applications

Skin and Hair loss

in endoscopy

Inflammatory Bowel Disease (IBD)

Colorectal cancer (CRC)

Colon - lesion detection

Acne

Irritable Bowel Syndrome - Diarrhoea

Colon - further applications

Androgenetic Alopecia

(IBS-D)

underway

Infectious diseases

Cosmo Pharmaceuticals | Half Year Results 2022

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Cosmo Pharmaceuticals NV published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 05:07:04 UTC.